The GSK-3 family as therapeutic target for myocardial diseases

Circulation Research

Volumn 116, Issue 1, 2015, Pages 138-149

  Lal, Hind ^a   Ahmad, Firdos ^a   Woodgett, James ^b   Force, Thomas ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

fibrosis; glycogen synthase kinase 3; heart failure; myocardial infarction

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; CARDIOVASCULAR AGENT; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3;

AGING; AUTOPHAGY; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE DELETION; HEART DEVELOPMENT; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHIES; DRUG DELIVERY SYSTEM; ENZYMOLOGY; METABOLISM; PROCEDURES;

ANIMALS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS;

EID: 84920815706     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.303613     Document Type: Review

References (83)

1. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9:2431-2438.
2. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 1993;12:803-808.
3. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell. 2006;24:627-633. doi:10.1016/j.molcel.2006.10.009.
4. Kirk JA, Holewinski RJ, Kooij V, Agnetti G, Tunin RS, Witayavanitkul N, de Tombe PP, Gao WD, Van Eyk J, Kass DA. Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β. J Clin Invest. 2014;124:129-138. doi:10.1172/JCI69253.
5. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, Sabio G, Davis RJ, Matthews DE, Doble B, Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science. 2008;320:667-670. doi:10.1126/science.1156037.
6. Matsuda T, Zhai P, Maejima Y, Hong C, Gao S, Tian B, Goto K, Takagi H, Tamamori-Adachi M, Kitajima S, Sadoshima J. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci USA. 2008;105:20900-20905. doi:10.1073/pnas.0808315106.
7. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2002;99:907-912. doi:10.1073/pnas.231619298.
8. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 2008;117:2761-2768. doi:10.1161/CIRCULATIONAHA.107.755066.
9. Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet S, Shah AM, Miura T, Yellon DM, Avkiran M, Marber MS. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res. 2008;103:307-314. doi:10.1161/CIRCRESAHA.107.169953.
10. Webb IG, Nishino Y, Clark JE, Murdoch C, Walker SJ, Makowski MR, Botnar RM, Redwood SR, Shah AM, Marber MS. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic betaadrenergic remodelling of the heart. Cardiovasc Res. 2010;87:494-503. doi:10.1093/cvr/cvq061.
11. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci. 2011;4:40. doi:10.3389/fnmol.2011.00040.
12. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD, Alessandrini A, Woodgett J, Hajjar R, Michael A, Force T. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000;151:117-130.
13. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, Sadoshima J. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem. 2000;275:14466-14475.
14. Cho J, Rameshwar P, Sadoshima J. Distinct roles of glycogen synthase kinase (GSK)-3alpha and GSK-3beta in mediating cardiomyocyte differentiation in murine bone marrow-derived mesenchymal stem cells. J Biol Chem. 2009;284:36647-36658. doi:10.1074/jbc.M109.019109.
15. Hirotani S, Zhai P, Tomita H, Galeotti J, Marquez JP, Gao S, Hong C, Yatani A, Avila J, Sadoshima J. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res. 2007;101:1164-1174. doi:10.1161/CIRCRESAHA.107.160614.
16. Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, Epstein JA, Force T, Huggins GS. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest. 2008;118:3609-3618. doi:10.1172/JCI36245.
17. Lal H, Ahmad F, Zhou J, Yu JE, Vagnozzi RJ, Guo Y, Yu D, Tsai EJ, Woodgett J, Gao E, Force T. Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart. Circulation. 2014;130:419-430. doi:10.1161/CIRCULATIONAHA.113.008364.
18. Zhou J, Lal H, Chen X, Shang X, Song J, Li Y, Kerkela R, Doble BW, MacAulay K, DeCaul M, Koch WJ, Farber J, Woodgett J, Gao E, Force T. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest. 2010;120:2280-2291. doi:10.1172/JCI41407.
19. Zhai P, Gao S, Holle E, Yu X, Yatani A, Wagner T, Sadoshima J. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overloadinduced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem. 2007;282:33181-33191. doi:10.1074/jbc. M705133200.
20. Lal H, Zhou J, Ahmad F, Zaka R, Vagnozzi RJ, Decaul M, Woodgett J, Gao E, Force T. Glycogen synthase kinase-3α limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. Circulation. 2012;125:65-75. doi:10.1161/CIRCULATIONAHA.111.050666.
21. Maejima Y, Galeotti J, Molkentin JD, Sadoshima J, Zhai P. Constitutively active MEK1 rescues cardiac dysfunction caused by overexpressed GSK-3α during aging and hemodynamic pressure overload. Am J Physiol Heart Circ Physiol. 2012;303:H979-H988. doi:10.1152/ajpheart.00415.2012.
22. Zhou J, Freeman TA, Ahmad F, Shang X, Mangano E, Gao E, Farber J, Wang Y, Ma XL, Woodgett J, Vagnozzi RJ, Lal H, Force T. GSK-3α is a central regulator of age-related pathologies in mice. J Clin Invest. 2013;123:1821-1832. doi:10.1172/JCI64398.
23. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86-90. doi:10.1038/35017574.
24. Michael A, Haq S, Chen X, et al. Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem. 2004;279:21383-21393. doi:10.1074/jbc.M401413200.
25. Woulfe KC, Gao E, Lal H, Harris D, Fan Q, Vagnozzi R, DeCaul M, Shang X, Patel S, Woodgett JR, Force T, Zhou J. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res. 2010;106:1635-1645. doi:10.1161/CIRCRESAHA.109.211482.
26. Webb IG, Sicard P, Clark JE, Redwood S, Marber MS. Myocardial stress remodelling after regional infarction is independent of glycogen synthase kinase-3 inactivation. J Mol Cell Cardiol. 2010;49:897-900. doi:10.1016/j.yjmcc.2010.07.021.
27. Zhai P, Sciarretta S, Galeotti J, Volpe M, Sadoshima J. Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion. Circ Res. 2011;109:502-511. doi:10.1161/CIRCRESAHA.111.249532.
28. Ahmad F, Lal H, Zhou J, Vagnozzi RJ, Yu JE, Shang X, Woodgett JR, Gao E, Force T. Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. J Am Coll Cardiol. 2014;64:696-706. doi:10.1016/j. jacc.2014.04.068.
29. Kuster DW, Sequeira V, Najafi A, Boontje NM, Wijnker PJ, Witjas-Paalberends ER, Marston SB, Dos Remedios CG, Carrier L, Demmers JA, Redwood C, Sadayappan S, van der Velden J. GSK3β phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: short communication. Circ Res. 2013;112:633-639. doi:10.1161/CIRCRESAHA.112.275602.
30. Cho J, Zhai P, Maejima Y, Sadoshima J. Myocardial injection with GSK-3β-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res. 2011;108:478-489. doi:10.1161/CIRCRESAHA.110.229658.
31. Force T, Woodgett JR. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem. 2009;284:9643-9647. doi:10.1074/jbc. R800077200.
32. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191-227. doi:10.1016/j.pharmthera.2010.04.005.
33. Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49:962-970. doi:10.1161/HYPERTENSIONAHA.106.079426.
34. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-1217. doi:10.1016/j. cell.2013.05.039.
35. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature. 2010;464:520-528. doi:10.1038/nature08982.
36. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA. Transient regenerative potential of the neonatal mouse heart. Science. 2011;331:1078-1080. doi:10.1126/science.1200708.
37. Leri A, Kajstura J, Anversa P. Mechanisms of myocardial regeneration. Trends Cardiovasc Med. 2011;21:52-58. doi:10.1016/j. tcm.2012.02.006.
38. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisén J. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98-102. doi:10.1126/science.1164680.
39. Kajstura J, Urbanek K, Rota M, Bearzi C, Hosoda T, Bolli R, Anversa P, Leri A. Cardiac stem cells and myocardial disease. J Mol Cell Cardiol. 2008;45:505-513. doi:10.1016/j.yjmcc.2008.05.025.
40. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005;23:845-856. doi:10.1038/nbt1117.
41. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, Ibacache M, Criollo A, Nemchenko A, Hill JA, Lavandero S. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011;2:e244. doi:10.1038/cddis.2011.130.
42. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007;12:957-971. doi:10.1016/j.devcel.2007.04.001.
43. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549. doi:10.1172/JCI19906.
44. Miura T, Tanno M. Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther. 2010;24:255-263. doi:10.1007/s10557-010-6234-z.
45. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res. 2002;90:377-379.
46. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol. 2007;43:564-570. doi:10.1016/j. yjmcc.2007.08.010.
47. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res. 2008;103:983-991. doi:10.1161/CIRCRESAHA.108.178970.
48. Murphy E, Steenbergen C. Does inhibition of glycogen synthase kinase protect in mice? Circ Res. 2008;103:226-228. doi:10.1161/CIRCRESAHA.108.181602.
49. Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol. 2011;51:607-613. doi:10.1016/j.yjmcc.2010.11.020.
50. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90:1055-1063.
51. Kerkelä R, Woulfe K, Force T. Glycogen synthase kinase-3beta - actively inhibiting hypertrophy. Trends Cardiovasc Med. 2007;17:91-96. doi:10.1016/j.tcm.2007.01.004.
52. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol. 2008;153 Suppl 1:S137-S153. doi:10.1038/sj.bjp.0707659.
53. Blankesteijn WM, van de Schans VA, ter Horst P, Smits JF. The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci. 2008;29:175-180. doi:10.1016/j. tips.2008.01.003.
54. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524-529. doi:10.1172/JCI31487.
55. Chen W, Frangogiannis NG. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta. 2013;1833:945-953. doi:10.1016/j.bbamcr.2012.08.023.
56. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest. 2010;120:254-265. doi:10.1172/JCI40295.
57. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, Regan JN, Rojas M, Willis M, Leask A, Majesky M, Deb A. Wnt1/βcatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 2012;31:429-442. doi:10.1038/emboj.2011.418.
58. Bergmann C, Akhmetshina A, Dees C, Palumbo K, Zerr P, Beyer C, Zwerina J, Distler O, Schett G, Distler JH. Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis. 2011;70:2191-2198. doi:10.1136/ard.2010.147140.
59. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res. 2008;57:274-282. doi:10.1016/j.phrs.2008.02.001.
60. Kapoor M, Liu S, Shi-wen X, Huh K, McCann M, Denton CP, Woodgett JR, Abraham DJ, Leask A. GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest. 2008;118:3279-3290. doi:10.1172/JCI35381.
61. Rao TP, Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010;106:1798-1806. doi:10.1161/CIRCRESAHA.110.219840.
62. Metcalfe C and Bienz M. Inhibition of GSK3 by Wnt signalling-two contrasting models. J Cell Sci. 2011;124:3537-3544.
63. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci. 2010;35:161-168. doi:10.1016/j.tibs.2009.10.002.
64. Kim W, Kim M, Jho EH. Wnt/β-catenin signalling: from plasma membrane to nucleus. Biochem J. 2013;450:9-21. doi:10.1042/BJ20121284.
65. Lam AP, Gottardi CJ. β-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol. 2011;23:562-567. doi:10.1097/BOR.0b013e32834b3309.
66. Guo Y, Xiao L, Sun L, Liu F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012;61:337-346.
67. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3:735. doi:10.1038/ncomms1734.
68. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, Alman BA. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615-6620. doi:10.1038/sj.onc.1203041.
69. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased betacatenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151:329-334.
70. Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, Alman BA. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA. 2002;99:6973-6978. doi:10.1073/pnas.102657399.
71. Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, Schett G, Distler JH. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis. 2012;71:761-767. doi:10.1136/annrheumdis-2011-200568.
72. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11:790-811. doi:10.1038/nrd3810.
73. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13:616-630.
74. Moustakas A, Heldin CH. The regulation of TGFbeta signal transduction. Development. 2009;136:3699-3714. doi:10.1242/dev.030338.
75. Bae E, Kim SJ, Hong S, Liu F, Ooshima A. Smad3 linker phosphorylation attenuates Smad3 transcriptional activity and TGF-β1/Smad3-induced epithelial-mesenchymal transition in renal epithelial cells. Biochem Biophys Res Commun. 2012;427:593-599. doi:10.1016/j.bbrc.2012.09.103.
76. Cohen-Solal KA, Merrigan KT, Chan JL, Goydos JS, Chen W, Foran DJ, Liu F, Lasfar A, Reiss M. Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β- mediated growth inhibition. Pigment Cell Melanoma Res. 2011;24:512-524. doi:10.1111/j.1755-148X.2011.00858.x.
77. Velden JL, Alcorn JF, Guala AS, Badura EC, Janssen-Heininger YM. c-Jun N-terminal kinase 1 promotes transforming growth factor-β1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3. Am J Respir Cell Mol Biol. 2011;44:571-581. doi:10.1165/rcmb.2009-0282OC.
78. Kamato D, Burch ML, Piva TJ, Rezaei HB, Rostam MA, Xu S, Zheng W, Little PJ, Osman N. Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation. Cell Signal. 2013;25:2017-2024. doi:10.1016/j.cellsig.2013.06.001.
79. Wang G, Matsuura I, He D, Liu F. Transforming growth factor-{beta}- inducible phosphorylation of Smad3. J Biol Chem. 2009;284:9663-9673. doi:10.1074/jbc.M809281200.
80. Chen X, Xu L. Mechanism and regulation of nucleocytoplasmic trafficking of smad. Cell Biosci. 2011;1:40. doi:10.1186/2045-3701-1-40.
81. Schmierer B, Tournier AL, Bates PA, Hill CS. Mathematical modeling identifies Smad nucleocytoplasmic shuttling as a dynamic signal-interpreting system. Proc Natl Acad Sci USA. 2008;105:6608-6613. doi:10.1073/pnas.0710134105.
82. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3-control Smad3 protein stability and modulate TGF-signaling. Genes Dev. 2008;22:106-120. doi:10.1101/gad.1590908.
83. Millet C, Yamashita M, Heller M, Yu LR, Veenstra TD, Zhang YE. A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J Biol Chem. 2009;284:19808-19816. doi:10.1074/jbc.M109.016667.